Boston, MA -- (SBWIRE) -- 05/10/2013 -- GlobalData has released its new PharmaPoint Drug Evaluation report, "Zonegran (Epilepsy) - Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.

View Full Report Details and Table of Contents

Zonegran (zonisamide) is an AED that was originally developed by Dainippon Sumitomo Pharma and was launched under the brand name Excegran in Japan in 1989. It was initially marketed by Elan in the United States as Zonegran starting in 2000, before Elan transferred its interests in the drug to Eisai in 2004. Eisai also markets Zonegran in Asia (including China) and Europe. Zonisamide is chemically classified as a sulfonamide and is unrelated to other marketed anticonvulsants. Although the precise MOA of zonisamide is unknown, it is thought to convey its anticonvulsant properties through action at sodium and calcium channels.

Scope

- Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Zonegran including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Zonegran for the top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and India

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Zonegran performance
- Obtain sales forecast for Zonegran from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and India)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022
- Fycompa (Epilepsy) - Forecast and Market Analysis to 2022